Thiophen urea derivatives as a new class of hepatitis C virus entry inhibitors.

J Enzyme Inhib Med Chem

College of Science and Engineering, Jungwon University, Geosan-gun, Chungbuk, Republic of Korea.

Published: December 2021

To develop unique small-molecule inhibitors of hepatitis C virus (HCV), thiophen urea (TU) derivatives were synthesised and screened for HCV entry inhibitory activities. Among them, seven TU compounds exhibited portent anti-viral activities against genotypes 1/2 (EC < 30 nM) and subsequently, they were further investigated; based on the pharmacological, metabolic, pharmacokinetic, and safety profiles, was selected as the optimised lead compound as an HCV entry inhibitor. possesses effective multi-genotypic antiviral activity. The docking results suggested the potential interaction of with the HCV E2 glycoprotein. These results suggest that can be a potential candidate drug for the development of HCV entry inhibitors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822064PMC
http://dx.doi.org/10.1080/14756366.2020.1870456DOI Listing

Publication Analysis

Top Keywords

hcv entry
12
thiophen urea
8
urea derivatives
8
hepatitis virus
8
entry inhibitors
8
hcv
5
derivatives class
4
class hepatitis
4
entry
4
virus entry
4

Similar Publications

Despite all the progress in treating SARS-CoV-2, escape mutants to current therapies remain a constant concern. Promising alternative treatments for current and future coronaviruses are those that limit escape mutants by inhibiting multiple pathogenic targets, analogous to the current strategies for treating HCV and HIV. With increasing popularity and ease of manufacturing of RNA technologies for vaccines and drugs, therapeutic microRNAs represent a promising option.

View Article and Find Full Text PDF

Background: Simplified approaches to HCV treatment delivery are needed to meet elimination goals. However, the impact of low-touch strategies on individuals at higher risk due to treatment failure or reinfection is unknown. We estimated HCV reinfection rates, and the impact of resistance associated substitutions (RASs) on response in the ACTG A5360 (MINMON) trial.

View Article and Find Full Text PDF

Unlabelled: Cells under stress shift their proteome by repressing cap-dependent translation initiation. RNA elements called internal ribosome entry sites (IRES) can allow key cellular transcripts to remain efficiently translated to support an effective stress response. Well- characterized IRESes depend on RNA structures that reduce the protein requirements for translation initiation, thus circumventing translation inhibition.

View Article and Find Full Text PDF
Article Synopsis
  • Chronic HCV infection affects about 50 million people worldwide, leading to significant mortality, necessitating the development of a vaccine that can handle the virus's high variability and evasion of antibodies.
  • The study found that while HVR1 insertions in the virus's envelope protein are rare (0.7% in routine sequencing), 3% of patients demonstrated these insertions, impacting the virus's ability to evade neutralizing antibodies (NAbs).
  • HVR1 insertions were shown to be viable in living organisms, affecting antibody sensitivity and suggesting that they play a key role in how HCV escapes immune responses during infection.
View Article and Find Full Text PDF

The prevalence of active hepatitis C virus (HCV) infection is higher in hospital emergency departments (EDs) than in the general population. Numerous patients who seek emergency care are unaware that they have detectable viremia, yet they fall outside established ED protocols for HCV screening. Often they belong to groups with difficult access to health care who use the ED as their point of entry to the system.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!